论文部分内容阅读
目的评价老年冠心病心律失常患者采取参松养心胶囊联合美托洛尔缓释片治疗的临床效果。方法将86例老年冠心病心律失常患者纳入本研究,按随机数字表法分为两组,对照组43例患者单用美托洛尔缓释片治疗,观察组43例患者采用参松养心胶囊联合美托洛尔缓释片治疗,进一步比较评价两组患者的临床疗效。结果观察组总有效率为95.3%,对照组为65.1%,差异有统计学意义(P<0.05)。治疗前,两组缺血发生次数、缺血总时间以及B型脑钠肽(BNP)水平比较差异均未见统计学意义(P<0.05);治疗后,两组患者以上三项指标均有改善;但观察组改善效果明显优于对照组(P<0.05)。此外,两组患者在不良反应方面比较差异未见统计学意义(P>0.05)。结论老年冠心病心律失常患者采用参松养心胶囊联合美托洛尔缓释片治疗具有显著疗效,值得临床采纳及应用。
Objective To evaluate the clinical effect of Shensong Yangxin Capsule combined with metoprolol sustained-release tablets in senile patients with coronary heart disease. Methods Eighty-six elderly patients with coronary heart disease were included in this study. According to the random number table, the patients were divided into two groups. In the control group, 43 patients were treated with metoprolol sustained- Capsules combined with metoprolol sustained-release tablets treatment, further evaluation of the clinical efficacy of two groups of patients. Results The total effective rate was 95.3% in observation group and 65.1% in control group, the difference was statistically significant (P <0.05). Before treatment, there was no significant difference between the two groups in the number of ischemia, the total time of ischemia and the level of BNP (P <0.05). After treatment, the above three indexes of both groups had Improvement; but the observation group improved significantly better than the control group (P <0.05). In addition, the two groups of patients showed no significant difference in adverse reactions (P> 0.05). Conclusion The treatment of elderly patients with coronary heart disease arrhythmia with Shensongyangxin capsules combined with metoprolol sustained-release tablets has a significant effect, it is worthy of clinical acceptance and application.